Global Patent Index - EP 1003521 A1

EP 1003521 A1 2000-05-31 - METHODS TO POTENTIATE INTRAVENOUS ESTRAMUSTINE PHOSPHATE

Title (en)

METHODS TO POTENTIATE INTRAVENOUS ESTRAMUSTINE PHOSPHATE

Title (de)

VERFAHREN ZUR POTENZIERUNG INTRAVENÖS ESTRAMUSTIN PHOSFAT

Title (fr)

PROCEDES DE POTENTIALISATION DE L'ESTRAMUSTINE PHOSPHATE INTRAVEINEUX

Publication

EP 1003521 A1 (EN)

Application

EP 99914884 A

Priority

  • US 9904275 W
  • US 7954298 P

Abstract (en)

[origin: WO9949869A1] Estramustine phosphate is an anti-mitotic chemotherapeutic drug with proven efficacy against cancer. The invention describes methods which potentiate the therapeutic benefit of intravenous estramustine phosphate. The invention provides for intravenous estramustine phosphate to be administrated at a high dosage exceeding 1300 mg as a single dose. Efficacious enhancement of estramustine phosphate pharmacokinetics is thereby achieved. Further provided, estramustine phosphate may be intravenously administered for use in combinational regimens with other chemotherapeutic agent. The therapeutic advantages achieved using the intravenous estramustine phosphate formulation are applicable to treatment of a variety of cancers including prostate cancer, breast cancer, lung cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and other cancers.

IPC 1-7 (main, further and additional classification)

A61K 31/56; A61K 9/127; A61K 31/335; A61K 31/44; A61K 31/65

IPC 8 full level (invention and additional information)

A61K 9/127 (2006.01); A61K 9/08 (2006.01); A61K 31/337 (2006.01); A61K 31/437 (2006.01); A61K 31/4468 (2006.01); A61K 31/565 (2006.01); A61K 31/704 (2006.01); A61K 31/7042 (2006.01); A61P 35/00 (2006.01)

CPC (invention and additional information)

A61K 9/08 (2013.01)

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9949869 A1 19991007; AU 3353399 A 19991018; AU 750010 B2 20020711; BR 9906425 A 20000711; CA 2295049 A1 19991007; CN 1273530 A 20001115; CN 1636598 A 20050713; EA 004647 B1 20040624; EA 199901081 A1 20001225; EP 1003521 A1 20000531; EP 1003521 A4 20030723; HU 0200547 A2 20020729; HU 0200547 A3 20030728; ID 24504 A 20000720; IL 133612 D0 20010430; JP 2001508810 A 20010703; KR 20010021656 A 20010315; NO 20002343 A 20000504; NO 20002343 D0 20000504; NZ 501987 A 20021025; PL 342969 A1 20010716; ZA 9907821 B 20000801

INPADOC legal status


2006-03-29 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20050924

2005-06-01 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: PHARMACIA & UPJOHN COMPANY LLC

2004-01-07 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20031119

2003-07-23 [A4] SUPPLEMENTARY SEARCH REPORT

- Effective date: 20030606

2000-05-31 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20000120

2000-05-31 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

2000-05-31 [AX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO

- Free text: SI PAYMENT 20000120